While Abivax ADR has overperformed by 2.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABVX rose by 1651.78%, with highs and lows ranging from $127.00 to $4.77, whereas the simple moving average jumped by 199.62% in the last 200 days.
On November 24, 2025, Truist started tracking Abivax ADR (NASDAQ: ABVX) recommending Buy. A report published by Wolfe Research on November 06, 2025, Initiated its previous ‘Outperform’ rating for ABVX. Barclays also rated ABVX shares as ‘Overweight’, setting a target price of $142 on the company’s shares in an initiating report dated October 13, 2025. Morgan Stanley initiated its ‘Equal-Weight’ rating for ABVX, as published in its report on March 20, 2025. JMP Securities’s report from December 04, 2024 suggests a price prediction of $33 for ABVX shares, giving the stock a ‘Mkt Outperform’ rating. Laidlaw also rated the stock as ‘Buy’.
Analysis of Abivax ADR (ABVX)
To gain a thorough understanding of Abivax ADR’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -147.48% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.77, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ABVX is recording an average volume of 1.15M. On a monthly basis, the volatility of the stock is set at 5.78%, whereas on a weekly basis, it is put at 6.24%, with a gain of 12.65% over the past seven days. Furthermore, long-term investors anticipate a median target price of $120.16, showing decline from the present price of $128.23, which can serve as yet another indication of whether ABVX is worth investing in or should be passed over.
How Do You Analyze Abivax ADR Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.61%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 55.54% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
